Scholar Rock (SRRK) surged 12% to near five-year highs after resubmitting its BLA for SMA drug Apitegromab. Raymond James raised the target to $60, citing strong uptake, while H.C. Wainwright called it a 'material de-risking event' with improved FDA alignment. Analysts see strong commercial potential, with a decision expected by September 2026.